Bosentan - Actelion

Drug Profile

Bosentan - Actelion

Alternative Names: Bosentan monohydrate; RO-470203; RO-470203-029; Tracleer

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Actelion Pharmaceuticals; Erasmus MC
  • Class Antihypertensives; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Skin ulcer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Skin ulcer
  • Phase II Behcet's syndrome
  • No development reported Diabetic foot ulcer
  • Discontinued Asthma; Heart failure; Inflammatory bowel diseases; Ischaemic heart disorders; Kidney disorders; Malignant melanoma; Myocardial infarction; Pulmonary fibrosis; Reperfusion injury; Transplant rejection

Most Recent Events

  • 06 Sep 2017 Registered for Pulmonary arterial hypertension (In children, In adolescents) (32mg) in USA (PO)
  • 06 Sep 2017 Actelion expects to make the 32mg dosage option of bosentan (Tracleer®) available in USA by the fourth quarter of 2017
  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top